Table 3.
Association of history of COVID-19 symptoms and seropositivity of anti-SARS-CoV-2 antibodies.
| COVID-19 symptoms in the past 6 months | SARS-CoV-2 antibodies |
Crude OR (95% CI;LL-UL) | p-value | |||
|---|---|---|---|---|---|---|
| Seronegative (n = 1355) |
Seropositive (n = 1564) |
|||||
| No. | % | No. | % | |||
| Fever | ||||||
| Yes | 284 | 36.7% | 489 | 63.3% | 1.715 (1.44–2.031)a | 0.000 |
| No | 1071 | 49.9% | 1075 | 50.1% | Ref. | |
| Cough | ||||||
| Yes | 444 | 42.8% | 594 | 57.2% | 1.256 (1.079–1.464)a | 0.003 |
| No | 911 | 48.4% | 970 | 51.6% | Ref. | |
| Diarrhea | ||||||
| Yes | 279 | 44.2% | 352 | 55.8% | 1.120 (0.938–1.337) | 0.210 |
| No | 1076 | 47.0% | 1212 | 53.0% | Ref. | |
| Dyspnea | ||||||
| Yes | 171 | 38.9% | 269 | 61.1% | 1.438 (1.169–1.769)a | 0.001 |
| No | 1184 | 47.8% | 1295 | 52.2% | Ref. | |
| Anosmia and/or Ageusia | ||||||
| Yes | 97 | 19.7% | 395 | 80.3% | 4.382 (3.4610–5.548)a | 0.000 |
| No | 1258 | 51.8% | 1169 | 48.2% | Ref. | |
| Rhinorrhea | ||||||
| Yes | 434 | 44.2% | 549 | 55.8% | 1.148 (0.984–1.339) | 0.080 |
| No | 921 | 47.6% | 1015 | 52.4% | Ref. | |
| Fatigue | ||||||
| Yes | 270 | 36.8% | 464 | 63.2% | 1.695 (1.427–2.013)a | 0.000 |
| No | 1085 | 49.7% | 1100 | 50.3% | Ref. | |
| Myalgia/arthralgia | ||||||
| Yes | 258 | 37.4% | 432 | 62.6% | 1.623(1.362–1.933)a | 0.000 |
| No | 1097 | 49.2% | 1132 | 50.8% | Ref. | |
| Eye redness | ||||||
| Yes | 90 | 41.3% | 128 | 58.7% | 1.253 (0.947–1.658) | 0.114 |
| No | 1265 | 46.8% | 1436 | 53.2% | Ref. | |
| Sleep problems | ||||||
| Yes | 123 | 34.9% | 229 | 65.1% | 1.718 (1.362–2.168)a | 0.000 |
| No | 1232 | 48.0% | 1335 | 52.0% | Ref. | |
| Number of reported COVID-19 symptoms | ||||||
| 0 | 527 | 52.5% | 477 | 47.5% | Ref. | |
| 1–2 | 412 | 49.5% | 420 | 50.5% | 1.126 (0.937–1.354) | 0.205 |
| 3–4 | 240 | 42.8% | 321 | 57.2% | 1.478 (1.200–1.820)a | 0.000 |
| 5+ | 176 | 33.7% | 346 | 66.3% | 2.172 (1.744–2.706)a | 0.000 |
a
Significant results p<0.05.